Premium
An In Vitro Model of HIPEC
Author(s) -
Strom David Kelly,
Hoy Samantha D.,
Huffman Ryan,
Stencel Mike,
Boettcher Jessica L.,
Hawkins Aruna A.,
Larsen Bryan
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.657.9
Subject(s) - hyperthermic intraperitoneal chemotherapy , hela , in vitro , doxorubicin , heat shock protein , mitomycin c , hsp70 , chemotherapy , cancer research , pharmacology , cytoreductive surgery , chemistry , medicine , cancer , surgery , biochemistry , ovarian cancer , gene
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a procedure that utilizes the combination of heat and chemotherapy to kill malignant cells of peritoneal carcinomas that may not be completely removed during cytoreductive surgery. HIPEC has been shown clinically to significantly increase the survival of patients receiving this therapy. In an effort to understand the biological basis of this procedure, we have developed an in vitro model of HIPEC using HeLa cells. HeLa cells show no deleterious effects from incubation at 41°C for 100 minutes. In response to chemotherapeutic agents, HeLa cells are significantly more sensitive to doxorubicin at 41°C as compared to 37°C. However, there was no difference in dose response to Mitomycin C at 41°C compared to 37°C. We also see a 2–4 fold increase in HSP90 protein levels when HeLa cells are incubated at 41°C for 100 minutes. Since Heat Shock Protein expression would likely dampen the killing effects of chemotherapeutic agents, we plan on looking at the expression of both HSP70 and HSP90 in this system, and then use specific HSP blockers to determine if we can potentiate the effects of the chemotherapeutic agents at 41°C. Our goal is to help understand the biological basis of HIPEC and to identify ways to make it even more effective.